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Background: Transgenic mice expressing disease-associated proteins have become standard tools for studying
human neurological disorders. Transgenes are often expressed using promoters chosen to drive continuous high-
level expression throughout life rather than temporal and spatial fidelity to the endogenous gene. This approach
has allowed us to recapitulate diseases of aging within the two-year lifespan of the laboratory mouse, but has the
potential for creating aberrant phenotypes by mechanisms unrelated to the human disorder.
Results: We show that overexpression of the Alzheimer’s-related amyloid precursor protein (APP) during early
postnatal development leads to severe locomotor hyperactivity that can be significantly attenuated by delaying
transgene onset until adulthood. Our data suggest that exposure to transgenic APP during maturation influences
the development of neuronal circuits controlling motor activity. Both when matched for total duration of APP
overexpression and when matched for cortical amyloid burden, animals exposed to transgenic APP as juveniles are
more active in locomotor assays than animals in which APP overexpression was delayed until adulthood. In contrast
to motor activity, the age of APP onset had no effect on thigmotaxis in the open field as a rough measure of
anxiety, suggesting that the interaction between APP overexpression and brain development is not unilateral.
Conclusions: Our findings indicate that locomotor hyperactivity displayed by the tet-off APP transgenic mice and
several other transgenic models of Alzheimer’s disease may result from overexpression of mutant APP during
postnatal brain development. Our results serve as a reminder of the potential for unexpected interactions between
foreign transgenes and brain development to cause long-lasting effects on neuronal function in the adult. The tet-
off APP model provides an easy means of avoiding developmental confounds by allowing transgene expression to
be delayed until the mice reach adulthood.
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One of the challenges in modeling age-associated dis-
eases in transgenic mice is the need to compress decades
of pathogenesis into the two-year lifespan of the labora-
tory mouse. This is often accomplished by overexpres-
sing disease-associated proteins at high levels from the
earliest age possible using strong promoters that are* Correspondence: jankowsk@bcm.edu
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reproduction in any medium, provided the oractive before birth. Over the past two decades, this ap-
proach has yielded several dozen mouse models of Alz-
heimer’s disease in which transgenic expression of the
amyloid precursor protein (APP) is controlled by pro-
moters such as the prion protein, Thy-1 cell surface anti-
gen, or platelet-derived growth factor B chain that drive
high-level transgene expression in the adult [1-5]. The
inclusion of one or more familial disease-causing muta-
tions alters the enzymatic processing of APP to increase
production of amyloid-β (Aβ) 42 peptide (reviewed in
[6,7], resulting in the formation of age-associated amyl-
oid deposits similar to those found in human Alzhei-
mer’s patients.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tic cognitive symptoms of Alzheimer’s disease. Many
APP transgenic models show cognitive decline reminis-
cent of the human disorder, and several also display
non-cognitive symptoms associated with the disease, in-
cluding anxiety [8-11], aggression [11-17], locomotor
hyperactivity [9,18-25] and circadian disturbances
[9,13,18,26-28]. In many cases, these non-cognitive phe-
notypes begin before the onset of amyloid deposition
[10-13,15,24,28], and in several models show little
change with disease progression [13,21,28] but see
[9,10,22,23]. The early appearance and persistent nature
of certain behavioral features are not consistent with the
gradual accumulation of Aβ, but rather point to a role
for the overexpression of mutant APP itself.
Although most of the behavioral and pathological
effects of transgene expression are measured in the
adult, APP overexpression in several of these models
begins during development. Promoters such as the prion
protein promoter, PDGF-B, and Thy-1 used to create
many common APP transgenic lines are all expressed in
the brain by mid-gestation, and have been used to rescue
embryonic lethality caused by gene deletion [29-32]. The
contribution of developmental APP expression to later
pathogenesis has been generally overshadowed by the
absence of obvious phenotypic changes until adulthood.
Moreover, recent transgenic models have incorporated
promoters such as calcium-calmodulin kinase IIα (CaM-
KIIα) thought to be inactive before birth, thereby avoid-
ing any prenatal effects of APP overexpression [33-35].
Contrary to these assumptions, we discovered an unex-
pected interaction between postnatal brain development
and transgenic overexpression of mutant APP that had
behavioral consequences in the adult. Here we show that
the severe locomotor hyperactivity displayed by several
of our tetracycline-controllable APP transgenic lines can
be substantially attenuated by delaying transgene expres-
sion until adulthood. Our findings indicate that even
phenotypes with relevance to disease may not arise by
the same mechanisms in transgenic models as in the
human disorder.
Results
Delaying transgenic APP overexpression until adulthood
attenuates motor hyperactivity
In our original characterization of the tet-off APP trans-
genic mice, we described severe hyperactivity due to
APP overexpression that prevented us from assessing
their performance on standard behavioral tasks [35].
These initial studies monitored animals over several
days and revealed abnormally high activity during both
phases of the light:dark cycle. Locomotor activity was
normalized by lifelong suppression of the transgene,
which demonstrated that the effect was not due toinsertion site, and was replicated in multiple tet-
responsive APP transgenic lines (i.e., line 107, 8–85, and
102, expressing the same transgene and created from the
same construct). While seeking a way to examine synap-
tic plasticity in lieu of cognition with this model, we ser-
endipitously discovered that the hyperactive phenotype
could be modified by delaying the onset of transgene ex-
pression. This experiment began by rearing APP/TTA
mice on doxycycline (dox) until they reached sexual ma-
turity (P1-P3 until P41-P43, Figure 1). This was initially
done to generate a series of animals in which the effects
of monomeric Aβ, oligomeric aggregates, and deposited
amyloid could be studied in acute brain slices from mice
that had all reached adulthood. Prior to harvesting the
animals for electrophysiological studies, we used the
mice to examine whether the aggregation state of Aβ
affected motor activity. This simple behavioral evalu-
ation led to the current study in which we describe the
interplay between postnatal brain development, trans-
genic APP overexpression, and motor hyperactivity in
the adult.
Three time points were chosen for analysis following
onset of transgenic APP: 7 wk after APP induction, just
prior to the onset of amyloid formation; 4 mo after APP
induction, when a sparse amyloid burden had accumu-
lated; and 1 mo after therapeutic suppression of APP
with dox to reduce Aβ production, without affecting
pre-existing deposits. We also tested adult-onset mice at
two additional time points that could not be examined
in juvenile-onset animals because of their age: 0 wk,
while animals were still on dox and 1 wk after APP in-
duction, when transgenic APP is fully expressed and Aβ
peptide is expected to have reached steady-state levels.
Motor activity was assessed by measuring ambulation –
defined as two consecutive photobeam breaks through a
frame surrounding the cage - during the first 30 min after
being placed into a clean cage. The manipulation was
similar to weekly cage changes, using the same shoebox
cage bottoms, isolator lids, and wood-chip bedding. Mice
were assessed individually during activity monitoring but
reunited with their siblings immediately afterwards.
As expected based on our past work with this line, we
found that overexpression of APP from birth resulted in
significant hyperactivity in the adult [35]. By 7 wk of age,
juvenile-onset APP/TTA mice were substantially more
active than their TTA single-transgenic siblings (2-way
RM-ANOVA, p< 0.01, Figure 2) and remained hyper-
active with continued transgene expression (4 mo, 2-way
RM-ANOVA, p< 0.01). On average, juvenile-onset APP/
TTA mice were more than twice as active as TTA con-
trols at 7 wk of age (2.2-fold increase, 2-way ANOVA,
post hoc p< 0.01, Figure 3) and more than 3 times as
active at 4 mo (3.2-fold increase, p< 0.001). While
therapeutic suppression of transgenic APP expression
Figure 1 Using doxycycline to control the onset of transgenic APP expression. The tet-off APP model uses TTA expressed from the CaMKIIα
promoter to control the expression of mutant APP. Under normal conditions, expression from this promoter begins during late embryogenesis
and transgenic APP is present at high levels by birth (juvenile onset). Transgene expression can be delayed by rearing the mice on dox, initially
transmitted to the pups through their mother’s milk. Dox treatment was used to suppress transgenic APP beginning from shortly after birth (P1-
P3) until adulthood (P41-P43). Transgenic APP expression was initiated at 6 wk of age by removing dox from the diet (adult onset). In both sets
of mice, bigenic (APP/TTA) and control (TTA) animals were behaviorally evaluated following 7 wk or 4 mo of transgene expression, and again
after 1 mo of therapeutic dox treatment to suppress APP expression after the formation of amyloid plaques (grey arrowheads). Adult-onset
animals were additionally evaluated immediately after removing dox (0 wk of APP expression), and 1 wk later (1 wk of APP expression) to assess
the impact of overproducing APP in the absence of Aβ accumulation. Behavioral testing at equivalent time points (P0 and P7) was not possible
in the juvenile-onset animals.
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tially reduced the severity of hyperactivity in the APP/
TTA mice, it did not eliminate it (2-way RM-ANOVA, p
< 0.05), despite past work demonstrating >90% reduc-
tion in transgene expression within 2–4 d of dox admin-
istration (JLJ, unpublished data). Ambulation remained
1.6-fold higher in APP/TTA mice than in TTA controls
after dox treatment, although the difference did not
reach statistical significance when averaged over time (2-
way ANOVA, post hoc p> 0.05).
Delaying the onset of APP overexpression until adult-
hood significantly reduced the degree of hyperactivity
we observed once transgene expression was initiated.
Immediately before (0 wk) and 1 wk after transgenic
APP expression began in the adult mice, motor activity
in adult-onset APP/TTA mice was identical to that in
TTA controls. Behavior did not diverge until 7 wk after
adult-onset APP overexpression, when average ambula-
tion was 1.4-fold higher in APP/TTA mice than in TTA
controls (2-way ANOVA post hoc p< 0.01). Average
ambulation remained constant at 1.4-fold control levels
at 4 mo (p< 0.05), but was then completely normalized
by 1 mo of therapeutic APP suppression (p> 0.05).
Perhaps as a result of increased motor activity,
juvenile-onset APP/TTA mice were noticeably smaller
and could be easily distinguished from their littermates.
Mean body weights were significantly lower in juvenile-
onset APP/TTA mice than in TTA controls at 7 wk (2-
way ANOVA, post hoc p< 0.01) and 4 mo (p< 0.05)
and this difference persisted after 1 mo of transgene sup-
pression (p< 0.05). In contrast, delaying APP overex-
pression until adulthood normalized body weight of
APP-overexpressing mice at all ages tested (2-way
ANOVA, p> 0.05).Age of onset does not influence the long-term level of
transgene expression
One possible explanation for diminished hyperactivity in
adult-onset mice is that the transgene may have been
expressed at lower levels following dox suppression
compared to expression levels in juvenile-onset mice. To
rule out this possibility, we examined full-length APP
levels from juvenile- and adult-onset APP/TTA mice
using the transgene-specific antibody 6E10 and the pan-
APP antibody CT15 (Figure 4). Expression was tested in
forebrain homogenates from P0 and P7 pups, 2 and 6
mo after juvenile onset, immediately prior to adult onset
(D0), and 7 d, 2 mo and 6 mo after adult onset.
Transgenic APP was present at birth in juvenile-onset
mice. Expression levels at P0 approached (6E10) or were
similar to (CT15) those found at later ages. Transgenic
APP thus appears earlier than has been reported for en-
dogenous CaMKIIα mRNA [36], but is consistent with
the late embryonic onset observed with tet-responsive
reporters for TTA activity in the CaMKIIα-TTA trans-
genic mice (M. Mayford, personal communication).
Transgenic APP expression remained high at P7 and
throughout adulthood.
In contrast to the immediate presence of transgenic
protein in juvenile-onset mice, transgenic APP in adult-
onset animals required several days to reach maximal
levels following withdrawal of dox. Once induced, ex-
pression of transgenic APP in adult-onset mice was simi-
lar, although not identical, to the levels observed in
juvenile-onset animals. We directly compared the levels
of full-length transgenic APP in juvenile- and adult-
onset mice following 2 mo and 6 mo of transgene ex-
pression by immunoblotting with 6E10. The level of
transgenic APP in adult-onset mice was 75.4 ± 4.1% of
Figure 2 (See legend on next page.)
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Figure 2 Juvenile onset of transgenic APP leads to significant motor hyperactivity that can be attenuated by delaying transgene
expression. A, B Locomotion was measured using an infrared photobeam system to track activity over time. Activity was identical in control
(TTA single-transgenic) and APP transgenic mice (APP/TTA double-transgenic) immediately prior to (0 wk, A; n = 21 TTA, n = 33 APP/TTA) and one
wk after the induction of transgenic APP expression in adult-onset mice (1 wk, B; n = 18 TTA, n = 19 APP/TTA). C, D Hyperactivity was apparent
after 7 wk of transgenic APP expression (top row) in both juvenile- (**p< 0.01; n = 23 TTA, n = 20 APP/TTA) and adult-onset mice (**p< 0.01,
n = 19 TTA, n = 20 APP/TTA). Both juvenile- (**p< 0.01, n = 12 TTA, n = 8 APP/TTA) and adult-onset mice (*p< 0.05, n = 11 TTA, n = 15 APP/TTA)
remain hyperactive with continued transgene expression, although the degree of variability and the magnitude of difference between control
and APP transgenic animals is greater with earlier onset (middle row). Suppression of transgene expression for 1 mo after 4 mo of overexpression
normalized ambulation levels in APP transgenic mice to that of controls following adult (p = 0.85; n = 15 TTA, n = 14 APP/TTA) but not juvenile-
onset (**p< 0.01; n = 15 TTA, n = 13 APP/TTA; bottom row). au: arbitrary units.
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post hoc p< 0.001), and 91.4 ± 2.1% at 6 mo (p> 0.05).
Thus, the expression of transgenic APP in adult-onset
mice was delayed by several days following dox with-
drawal and was approximately 25% lower for several
weeks afterwards, but ultimately reached levels similar
to those in juvenile-onset animals.
Delaying expression of transgenic APP slows the onset of
amyloid deposition but does not affect subsequent
accumulation
Another potential explanation for reduced hyperactivity
in the adult-onset mice was that the diminished trans-
gene expression following dox withdrawal did not yield
enough Aβ to form either soluble aggregates or amyloid
deposits within the 4 mo window of our experiments.
To rule out this possibility, we measured the percent of
cortical surface area covered by amyloid deposits in
silver-stained sections from juvenile- and adult-onset
APP/TTA mice at 2, 4, 6, 9, and 12 mo after APP induc-
tion. We found that the exponential phase of plaque de-
position was delayed following adult onset of APP
expression (2-way ANOVA, p< 0.001, Figure 5), but
once started, the rate of amyloid accumulation was simi-
lar in both groups of mice (p> 0.05). Consistent with
this overall shift in the curve, post hoc comparisons
reflected higher amyloid levels at 9 and 12 mo of APP
overexpression (p< 0.01 and p< 0.05, respectively) in
juvenile- compared to adult-onset mice.
Biochemical measures of Aβ concentration paralleled
histological measures of plaque load. The accumulation
of Aβ in adult-onset mice eventually reached the same
milestones as juvenile-onset animals, but did so at a
slightly later age. Two-way ANOVA revealed that over-
all, adult-onset mice harbored lower levels of SDS-
soluble (p< 0.05) and formic acid-soluble (p< 0.0001)
Aβ (40 + 42) than juvenile-onset animals. Post hoc com-
parisons indicated higher levels of formic acid-soluble
Aβ in juvenile-onset mice at 9 and 12 mo of APP over-
expression (p< 0.05 and p< 0.001, respectively).
To obtain an estimate of the temporal shift in amyloid
formation caused by delaying APP overexpression, we fit
the curves to polynomial equations and solved for age atvarying levels of amyloid burden. The age at which
adult-onset mice reached 20%, 30%, and 40% surface
area was on average 6 wk later than juvenile-onset
(range: 1.41-1.45 mo). This time is coincidentally the
same as the delay in APP overexpression until adult-
hood, but because the data are already corrected to de-
pict amyloid load at equivalent durations of transgene
expression, this reflects an additional delay that was
likely caused by the initial lag in transgene onset and
slight reduction in APP expression levels during the first
few months afterwards.
Locomotor hyperactivity is independent of amyloid
burden
Our discovery that amyloid burden was consistently
lower in adult-onset mice than in juvenile-onset mice
raised the possibility that ambulation differences we
observed in mice matched for duration of APP overex-
pression were due simply to a difference in plaque load
and not to a sustained change in motor behavior. To
rule out this possibility, we generated 3 new cohorts of
animals. One set of animals was allowed to overexpress
APP from birth and was tested at 6 mo of age. The other
two groups of mice were reared on dox until 6 wk of
age; one group was tested 6 mo later and the other 8 mo
later. These three groups allowed us to test the role of
APP onset and amyloid burden in motor hyperactivity
by comparing behavior in mice with 1) equal duration of
APP overexpression but different amyloid burden (6 mo
juvenile onset vs. 6 mo adult onset), 2) equal amyloid
burden but different age of onset (6 mo juvenile onset
vs. 8 mo adult onset), and 3) equal age of onset but dif-
ferent amyloid burden (6 mo adult onset vs 8 mo adult
onset). These ages were chosen to represent a stage of
disease more likely to be used for cognitive testing than
the beginning phase of pathology we studied in our first
experiments. Because our laboratory moved from Cal-
tech to Baylor between completing the original ambula-
tion studies and beginning these, we were restricted to
measuring locomotor activity by the less expensive and
more common open field assay. However, this offered
the opportunity to confirm our phenotype with an inde-
pendent behavioral test, and to assess locomotor activity
Figure 3 Delayed expression of transgenic APP reduces motor hyperactivity and normalizes body weight. A, B Comparison of mean
ambulation recorded by infrared photobeam monitoring highlights the severity of hyperactivity observed in juvenile-onset APP transgenic animals
(a) and the substantial reduction in this phenotype achieved by delaying onset until adulthood (b). Although reduced in magnitude with later
onset, post-test analyses identified significant differences between genotypes for both adult- and juvenile-onset at 7 wk and 4 mo (**p< 0.01 for
both at 7 wk; ***p< 0.001, for juvenile onset and *p< 0.05 for adult onset at 4 mo). C, D Replotting the data as individual values illustrates the
wide range of locomotor activity seen in mice overexpressing APP from birth and the substantial decrease in both variance and average attained
by delaying transgene onset. Individual mean ambulation is shown for juvenile vs. adult onset after 7 wk (C) and 4 mo (D) of transgenic APP
expression. Post-test comparisons of groups matched for duration of expression magnifies the difference between genotypes for juvenile onset
(***p< 0.001) but diminishes the difference for adult onset (p> 0.05 at both ages). E, F Mean body weight of APP-overexpressing mice is lower
than controls at 7 wk (**p< 0.01) and 4 mo (*p< 0.05) in juvenile onset mice, and this difference persisted even after 1 mo of transgene
suppression (*p< 0.05). Delaying transgene onset until adulthood normalized body weight of APP-overexpressing mice at all ages tested.
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cognitive testing.
Consistent with our earlier results, overexpression of
transgenic APP from birth leads to significant hyperactiv-
ity in the open field at 6 mo of age (ANOVA, p< 0.0001,
Figure 6). Juvenile-onset APP/TTA mice traveled a greateraverage distance during the 30 min test than any other
genotype (post hoc p< 0.001 vs. NTG, APP, and TTA).
Also consistent with our earlier findings, delaying the
onset of APP overexpression until adulthood significantly
attenuated, but did not completely extinguish, this hyper-
activity. Adult-onset APP/TTA mice with 6 mo of APP
Figure 4 Adult expression of transgenic APP is independent of age at onset. A Cortical homogenates from juvenile- and adult-onset
animals with 0 wk, 1wk, 2 mo or 6 mo of transgenic APP overexpression were immunoblotted with human-specific antibody 6E10 to determine
whether timing of onset of APP induction differentially alters forebrain APP expression. The blot was overexposed to visualize the small amount
of transgenic leak present in dox-treated mice (0 d, adult-onset). The outlined inset panel shows the same samples loaded with less protein per
lane and a shorter exposure time. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was co-immunostained as a loading control. B A
separate blot was immunostained with CT15; GAPDH was co-stained as a loading control. As in panel A, the intensity of GAPDH staining was
lower in perinatal samples (0 d harvested at P0 and 1 wk harvested at P7) than in adult tissue although similar amounts of protein were loaded
in each lane. The same GAPDH expression pattern was replicated with independent samples, and was observed with an unrelated control
protein, SOD1 (not shown). C, D Quantitation of signal intensity for full-length APP from the 6E10 Western blot shown in (A) and the CT15 blot
shown in (B). Because GADPH levels change over postnatal development, APP levels are plotted as absolute values rather than relative ratios.
Graphs show mean± SEM, n= 2 per time point for each age of onset. With just 2 samples per group, these values are intended only to highlight
the difference in APP levels at the outset of expression (0 d). E Immunoblotting with 6E10 in a larger cohort of animals was used to obtain a
more accurate measure of full-length APP expression after 2 mo and 6 mo of transgene expression. F Quantitation of APP intensity at 2 and 6
mo reveals that transgenic protein was lower in adult- than in juvenile-onset mice after 2 mo of expression (***p< 0.001), but reached similar
levels at 6 mo (n.s.). Values are calculated relative to GAPDH, which expressed at stable levels in adult mice. Because separate blots were used to
quantify APP levels at 2 mo and 6 mo, values for adult-onset were normalized to juvenile-onset at each age. Graph shows mean± SEM, n= 6-9
per time point for each age of onset. White bars, juvenile onset; black bars, adult onset.
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distance than other genotypes (ANOVA, post hoc p< 0.05
vs. NTG, APP, and TTA), but significantly less than
juvenile-onset APP/TTA mice with the same duration of
APP overexpression (2-way ANOVA, post hoc p< 0.001).
This comparison demonstrates that our findings from
open field testing were consistent with those obtained by
infrared activity frames, and that differences in motor ac-
tivity present earlier in the progression of pathology per-
sisted to later stages.
Interestingly, data from both juvenile- and adult-onset
APP/TTA mice were bimodally distributed. A minorfraction of the animals ran distances> 500 m, while the
remainder ran< 250 m. Delaying transgene onset
reduced the fraction of mice exhibiting this extreme be-
havior (5/15 or 33% following juvenile onset, 4/26 or
15% following adult onset). In some experimental set-
tings, mice with such high activity levels might be con-
sidered outliers. When these animals are removed from
analysis, the difference between juvenile-onset APP/TTA
mice and their siblings remained (ANOVA, post hoc p
< 0.001 vs NTG, APP, and TTA), while the difference
between adult-onset APP/TTA mice and their siblings is
lost (p> 0.05). This indicates that a small number of
Figure 5 Amyloid burden and Aβ levels are slightly delayed by adult onset APP overexpression. A, Silver staining shows forebrain
amyloid burden after 2, 4, 6, 9 and 12 mo of transgenic APP overexpression following juvenile (top row) or adult onset (bottom row). B,
Quantitation of cortical amyloid burden from silver-stained sections demonstrates that delaying APP overexpression slows initiation of the
exponential phase of plaque deposition (p< .001), although once underway the rate of amyloid accumulation is similar in both groups. Post hoc
comparisons indicate significant differences in amyloid burden at 9 mo (**p< 0.01) and 12 mo (*p< 0.05) of APP overexpression. n = 3-4 per
genotype at each time point. C, D Biochemical measures of Aβ concentration parallel histological measures of amyloid load. After equivalent
durations of APP overexpression, adult onset is associated with lower levels of both SDS- and FA-soluble Aβ (Aβ 40 plus 42; p< 0.05 (SDS),
p< 0.0001 (FA)). Additionally, the rate of change in FA-soluble Aβ is slower following adult onset (p< 0.001). Post hoc comparisons indicate
significant differences in FA-soluble Aβ at 9 mo (*p< 0.05) and 12 mo (***p< 0.001) of APP overexpression. Graphs show mean± SEM. n = 6-8
per genotype at each time point. Open symbols, juvenile onset; closed symbols, adult onset.
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types in adult-onset mice, and that when these animals
are identified and removed, the remaining cohort is
similar in motor activity to single- and NTG controls.
This was not true in juvenile-onset mice where the ma-
jority of APP/TTA mice are behaviorally distinct from
their siblings.We next compared open field activity between
juvenile- and adult-onset mice that were matched for
amyloid load rather than duration of APP overexpres-
sion. For this comparison, we tested APP/TTA mice that
were reared on dox until 6 wk of age and assayed in
open field 8 mo later against APP/TTA mice that were
never on dox and tested at 6 mo of age. Based on the
Figure 6 Delaying the onset of APP overexpression attenuates hyperactivity but not anxiety in the open field assay. An independent
cohort of animals was tested by open field assay at a single time point following 6 mo of APP overexpression. A A fraction of APP/TTA mice in
both juvenile and adult onset groups show extreme hyperactivity, traveling >500 m in 30 min (5/15 juvenile onset, 4/26 adult onset), but most
cover distances closer to the average of the other genotypes. B While both adult- and juvenile-onset APP/TTA mice travel greater average
distances than other genotypes (p< 0.0001), delaying the onset of transgene expression significantly diminished hyperactivity compared to
juvenile onset (***p< 0.001). C Juvenile-onset APP/TTA mice travel a smaller fraction of their total path within the center of the open field arena
than control mice (p< 0.001 vs. NTG and APP, p< 0.01 vs. TTA). This difference is not normalized by delaying the onset of transgene expression.
The only genotype for which dox rearing significantly altered path in center was APP (*p< 0.05). D A separate cohort of NTG and APP/TTA mice
was reared on dox until 6 wk of age and then tested in the open field 8 mo later. Data from the 8 mo adult-onset mice are plotted alongside 6
mo juvenile-onset mice taken from panel A to provide a comparison of open field activity in mice matched for amyloid load rather than duration
of APP overexpression. Again, delaying transgene onset reduces the fraction of mice displaying extreme hyperactivity (2/37 adult onset, 5/15
juvenile onset). E Average distance traveled is significantly reduced by delaying transgene onset (***p< 0.001). While open field activity of
juvenile-onset APP/TTA mice is significantly higher than their NTG siblings (p< 0.05), adult-onset APP/TTA mice are no different than age-
matched NTG controls (p> 0.05). F Despite significant attenuation of locomotor hyperactivity, delaying APP overexpression does not alter anxiety
measured as % path in the center of the open field arena.
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den in adult-onset mice at this age is approximately
14.3%, up from 2.9% two months earlier, and a better
match for the 9.3% burden found in juvenile-onset mice
at 6 mo of age. Even with slightly more amyloid and 2
mo longer exposure to transgenic APP, adult-onset APP/
TTA mice following 8 mo of APP over-expression were
significantly less active in the open field than juvenile-
onset mice at 6 mo (2-way ANOVA, post hoc p< 0.001).
Fewer APP/TTA mice displayed extreme hyperactivity in
the adult-onset group (2/37 or 5% vs. 5/15 or 33%), and
as at 6 mo, when these highly active animals were
removed from analysis, the remaining adult-onset APP/
TTA mice were no different than NTG (ANOVA, p
> 0.05). Further, there was no difference in open field
activity between the two groups of adult-onset APP/
TTA mice tested after 6 and 8 mo of APP overexpres-
sion (2-way ANOVA, post hoc p> 0.05), suggesting that
although amyloid burden increased almost 5 fold during
that time, locomotor activity did not. Moreover, there
was no difference in total distance traveled by NTG
mice under the two conditions, indicating that the 3.5mo age difference likely did not play a significant role
normalizing activity in the adult-onset APP/TTA mice.
Delaying the onset of transgenic APP expression does not
normalize all behavioral phenotypes
Open field testing also provided a coarse measure of
anxiety, another common phenotype in APP transgenic
mice. Highly anxious or neophobic animals tend to re-
main close to the walls of the chamber when examined
in the open field test, and the severity of this phenotype
can be roughly assessed by calculating how much time
the animal spends, or how far it travels, in the center of
the arena as a fraction of the total exploration time or
distance [37,38]. Compared to single transgenic and
NTG controls, 6 mo old juvenile-onset APP/TTA mice
traveled a significantly smaller fraction of their total path
length in the center of the arena (ANOVA, p< 0.001).
While 32.1 ± 1.5% of the path traveled by NTG mice was
spent in the center area, only 21.9 ± 1.8% was spent in
the center by APP/TTA mice (post hoc p< 0.001 vs.
NTG and APP, p< 0.01 vs. TTA). Delaying transgene
onset until adulthood did not abate thigmotaxis in the
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traveled significantly less of their total path in the center
of the arena than single transgenic and NTG controls
(ANOVA, p< 0.001). The percentages were similar to
juvenile-onset values: 30.9 ± 1.0% of the path traveled by
dox-reared NTG was spent in the center area, while only
23.8 ± 1.2% was spent in the center by APP/TTA mice
(post hoc p< 0.001 vs. NTG, p< 0.05 vs. TTA). Open-
field thigmotaxis persisted at 8 mo after adult onset,
when APP/TTA mice traveled 23.3 ± 1.4% of their path
in the center vs. 30.4 ± 1.1% in age-matched dox-reared
NTG animals (2-way ANOVA, p< 0.001). Like total dis-
tance traveled, the percent path in center did not differ
between 6 and 8 mo after transgene onset, indicating
that although amyloid burden increased, anxiety did not.
Although for now limited to this single measure of emo-
tionality, our findings suggest that delaying the onset of
APP overexpression does not unilaterally affect all be-
havioral phenotypes.
Discussion
During our initial characterization of the tet-off APP
transgenic lines in 2005 we noted motor hyperactivity
during both light and dark phases of the light cycle that
was severe enough to preclude cognitive analysis [35].
Here we show that this motor hyperactivity can be sub-
stantially attenuated by delaying overexpression of the
mutant protein until adulthood. This finding suggests
that the postnatal brain is susceptible to APP overex-
pression in a way that the mature brain is not. Exposure
to transgenic APP during postnatal development had
long-lasting effects on adult brain function that were
exacerbated by continued expression of mutant APP.
However, motor hyperactivity in juvenile-onset mice per-
sisted at a modest level even after therapeutic suppres-
sion of transgenic APP, indicating that once established,
the behavior is no longer dependent on continued APP
overexpression to be maintained.
Our findings are consistent with past reports describ-
ing motor hyperactivity in several other lines of APP
overexpressing mice. Significant elevations in open field
activity and home cage ambulation have been described
in both Tg2576 and CRND8 models [9,13,19-22]. Both
of these transgenic lines are controlled by the prion pro-
tein promoter [2,5], which in other transgenic models is
active in the brain before birth [30]. As with the CaM-
KIIα promoter used here, overexpression of transgenic
APP from the prion protein promoter would be
expected by the second postnatal week when the nigros-
triatal pathway undergoes considerable structural matur-
ation [39]. Endogenous APP plays a role in shaping
neuronal morphology and establishing synaptic connec-
tions during development, and loss of APP through tar-
geted deletion in vivo or by shRNA knockdown in vitroresults in neurite overgrowth and excessive, but poorly
aligned, pre- and post-synaptic structures [40-43],
reviewed in [44]. Paradoxically, overexpression of APP
can cause similar changes in immature neurons, increas-
ing neurite outgrowth and the density of dendritic spines
[45,46]. In vivo, the effect of APP overproduction on
neuron morphology is often confounded by the concur-
rent accumulation of Aβ in models expressing FAD
mutations. However, overexpression of wild-type APP –
absent the Aβ overproduction of FAD variants – leads
to increased synapse density both in the brain and in the
periphery [47-49]. Taken together, changes in APP ex-
pression (both up and down) can affect neuronal out-
growth and synapse formation in the brain and would be
present at the right time and place to modify neural cir-
cuitry in the maturing nigrostriatal pathway.
While delaying the onset of transgenic APP until
adulthood reduces the severity of motor hyperactivity, it
does not completely eliminate the behavior. Slight but
significant increases in ambulation developed by 7 wk of
APP overexpression and persisted at the same level
when tested at 4 mo. However, unlike the residual
hyperactivity that remained following therapeutic APP
suppression in mice with juvenile transgene expression,
1 mo of dox treatment completely normalized motor ac-
tivity in adult-onset mice. This indicates that in adult-
onset mice, motor hyperactivity was dependent on the
presence of transgenic APP. Consistent with this, past
work has shown that infusion of Aβ into the brains of
wild-type mice can acutely modulate dopamine release
[50,51]. However, the initial lag between induction of
transgenic APP by 1 wk after dox withdrawal (Figure 5)
and the appearance of hyperactivity at 7 wk (Figure 3)
suggests that the behavioral phenotype was not a direct
effect of APP overproduction. Instead, the delay between
transgene induction and the appearance of hyperactivity
suggests that the effect may be indirect, perhaps through
functional changes in the nigrostriatal pathway, such as
modulation of dopamine receptor sensitivity, alterations
in dopamine production, or transmitter uptake. Consist-
ent with this possibility, APP/PS1 transgenic mice show
altered tyrosine hydroxylase immunoreactivity and
diminished size of dopaminergic neurons within the sus-
bstantia nigra long before the appearance of amyloid
[52]. Alternatively, the delay between transgene induc-
tion and behavioral changes in the adult-onset mice (i.e.,
activity after 1 wk of APP over-expression was identical
to NTG but by 7 wk became significantly elevated) may
suggest dependence on the accumulation of an aggre-
gated, but reversible, form of Aβ. Further experiments,
such as in vivo microdialysis to measure striatal dopa-
mine release, or secretase inhibition to prevent Aβ pro-
duction during continued APP expression, will be
needed to distinguish these possibilities.
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type can be modulated independently from amyloid
pathology. Hyperactivity began prior to amyloid forma-
tion, in both juvenile- and adult-onset mice. In both
groups, cortical plaque burden was< 0.05% after 2 mo
of APP overexpression, yet ambulation was already ele-
vated a week earlier at 7 wk. Hyperactivity worsened
after amyloid formation in juvenile-onset mice, but
remained unchanged from pre-deposit levels in adult-
onset animals. The dissociation between plaques and
motor activity was most pronounced following thera-
peutic suppression of transgenic APP. Dox treatment
begun after the appearance of amyloid deposits has been
shown to stabilize plaque burden, preventing further ac-
cumulation but not promoting clearance [35,53]. APP
suppression completely normalized motor activity in
adult-onset mice and significantly reduced hyperactivity
in juvenile-onset animals, despite the continued pres-
ence of amyloid in both.
There are three caveats to our interpretation that are
worth noting. The first is that as late as 2 mo after onset,
the level of transgene expression in dox-reared animals
is not identical to dox-naïve. Although the level of APP
overexpression following adult-onset ultimately matches
that of juvenile-onset mice, it starts off approximately
25% lower. If the absolute level of transgenic APP and
not the age at which it is expressed is the critical factor
in determining hyperactivity, we may have mistaken a
concentration difference for an effect of timing. That
other APP transgenic models with lower expression
levels also display motor hyperactivity suggests this is
not the case. There is likely a minimum level of mutant
APP expression needed to evoke this phenotype, as a
companion line of tetO-APPswe/ind mice generated at
the same time as the line used here, but which produced
approximately one-quarter the amount of transgenic
APP, did not develop motor hyperactivity (line 70, data
not shown). The adult-onset mice studied here
expressed well in excess of this minimum, but the fact
that they expressed at lower levels for several months
and started almost a week later than juvenile-onset ani-
mals (once embryonic expression and the delay between
dox withdrawal and transgene onset are taken into ac-
count) meant that they also developed amyloid at a later
age. If the absolute amyloid levels were a critical factor
in determining hyperactivity, a better experimental de-
sign would have matched adult- and juvenile-onset ani-
mals for plaque burden rather than duration of APP
expression. In most of our comparisons, amyloid load
was lower in adult-onset animals (0.26 ± 0.038% vs.
1.6 ± 0.18% after 4 mo of transgenic APP expression,
2.92 ± 0.49% vs. 9.31 ± 0.67% at 6 mo). However, under
conditions that matched amyloid load rather than dur-
ation of APP overexpression (14.3% at 8 mo after adultonset (calculated), and 9.3% at 6 mo after juvenile onset
(actual)), hyperactivity was still greater in mice that
expressed APP from birth. This leads into the final cav-
eat to our interpretation of the data. In several of our
experiments, the magnitude of the difference in open
field ambulation and ambulation is driven by a small
number of outliers. While the size of the effect shrinks
when these animals are removed from analysis, the sig-
nificance remains. Thus, the behavioral impact of trans-
genic APP during postnatal development is fully
penetrant, albeit highly variable in scale.
Conclusions
Transgenic models based on APP overexpression have
been extraordinarily successful in recapitulating the late-
onset pathology of Alzheimer’s disease within the two-
year lifespan of the laboratory mouse. Their widespread
use makes the artificial nature of these models easy to
look past, but forcing amyloid formation to occur in
1 year or less generally requires expression of mutant
protein at levels several-fold higher than normal using
promoters that are active in temporal and spatial pat-
terns distinct from the endogenous gene. Here we show
that developmental overexpression of APP can cause
lasting changes in the behavior of adult animals that per-
sist even after the transgene is suppressed. While we
suspect only a limited number of behavioral phenotypes
observed in APP transgenic mice arise from develop-
mental interactions, our findings are a reminder of the
inherent limitations of our models. Given that many be-
havioral tests used to examine learning and memory in
rodents rely on controlled locomotor activity (i.e., fear
conditioning, Y-maze, object recognition, etc.), hyper-
active animals may be mistakenly considered cognitively
impaired, and successful therapies may simply normalize
motor function. The tet-controllable nature of our
model offers an easy means of limiting this issue and
opens the possibility of disentangling the developmental
consequences of APP overexpression from adult-onset
changes. The presence of excess APP in the adult may
yet have additional consequences for neural function un-
related to disease that remain a constant caveat when
working with model systems. Provided we acknowledge
their limitations and apply due caution, transgenic mice
offer an unparalleled platform for testing hypotheses and
refining how we think about disease.
Methods
Mice
Male and female tetracycline-responsive APP transgenic
mice were derived from the intercross of line 102 tetO-
APPswe/ind expressing a chimeric mouse APP with a
humanized Aβ domain and the Swedish and Indiana
mutations (MMRRC #34845, distributed via Jackson
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the tetracycline transactivator under control of the CaM-
KIIα promoter (Jackson Laboratories #3010 [54]) to gen-
erate APP/TTA double transgenic males for breeding.
Both lines had been backcrossed to C57BL/6 J for >20
generations prior to the intercrossing. The APP/TTA
males were then mated with wild-type C57BL/6 J
females to produce offspring for analysis. All pups were
fostered to outbred ICR females for rearing to improve
viability and avoid cannibalism of pups common in inex-
perienced C57BL/6 J breeders [55]. Equal numbers of
male and female offspring were used for study. Animal
experiments were performed under protocols that were
reviewed and approved by the Institutional Care and
Use Committee at either California Institute of Technol-
ogy or Baylor College of Medicine.
Doxycyclince treatment
One half of the animals used for study were reared on
doxycycline to suppress APP overexpression for the first
6 weeks of life. This was initially done by feeding dox
chow to nursing females who transmitted the drug
through their milk to the pups, and then continued by
maintaining the pups on dox chow after weaning. At
6 weeks of age, the mice were returned to regular (unme-
dicated) chow to initiate transgenic APP expression. Dox
was not initiated until between P1 and P3 to avoid pro-
blems associated with continuous suppression. Past work
has shown mice receiving dox from conception to adult-
hood express the transgene at lower levels than expected
when the drug is removed [56]. This is consistent with
DNA modification such as methylation of silent regions,
and has been exploited in past studies as a way to generate
transgenic mice from the same line with 30-60% of the
expected level of expression.
During the course of this study, and coinciding with
our move from California Institute of Technology to
Baylor College of Medicine, we discovered that trans-
genic APP expression in line 102 could be suppressed
equally well with 50 mg/kg doxycycline as with the ori-
ginal concentration of 200 mg/kg (JLJ, HAB, unpub-
lished data). Animals reared at Caltech and tested by
infrared beam activity frames described below were
therefore treated with the original chow formulated at
200 mg/kg doxycycline (F4845; BioServe, Frenchtown,
NJ) while animals reared at Baylor and used for open
field assay, biochemistry, and histology were treated with
chow containing 50 mg/kg doxycycline (F5903), both
formulated into a base diet of Purina 5001 rodent chow.
Activity monitoring
Animals were separated into clean cages immediately
before the start of each experiment. The cages were
placed inside photobeam frames to monitor the animals’movement over time (San Diego Instruments, San
Diego, California, United States). Experiments were
started midway through the light phase of the day, and
data was collected in 1 min bins for 30 min. Testing
rooms were maintained on the same 13:11 h day:night
cycle as the main animal housing areas and were closed
to entry during the experiment.
Open field assessment
Each mouse was placed in the center of an open-top
white acrylic box (20 in. x 20 in. x 9 in.) and allowed to
explore freely for 30 minutes. Movement was recorded
and analyzed using the ANY-maze Video Tracking Sys-
tem (Stoelting Co., Wood Dale, IL). The center of the
arena was defined as a square occupying 1/3 of the total
area, and the distance traveled in this field was calcu-
lated as a percentage of total distance traveled in the
arena.
Tissue harvest
Animals were perfused with PBS and the isolated
brains hemisected along the midline. One hemisphere
was frozen for biochemical analyses; the other hemi-
sphere was immersion-fixed for 48–96 hr at 4°C in 4%
paraformaldehyde.
ELISA
Hemi-forebrain samples were prepared for analysis of
Aβ levels by two-step sequential extraction using 2%
SDS followed by 70% formic acid (FA) as previously
described [57]. Aβ levels were determined by end-
specific sandwich ELISAs using mAb 2.1.3 for capture
(human Aβx-42 specific) and HRP-conjugated mAb Ab9
(human Aβ1–16 specific) for detection, or mAb Ab9 for
capture and HRP-conjugated mAb 13.1.1 (human Aβx-
40 specific) for detection [58,59]. All values were calcu-
lated as pmol per g based on the initial weight of brain
tissue.
Immunoblotting
The 2% SDS homogenates prepared for ELISA were
diluted 1:1 with 2x-concentrated high-detergent RIPA
buffer minus SDS (2xPBS, 1% deoxycholate, 1% NP40,
5 mM EDTA, plus protease inhibitors). Protein concen-
tration was measured by BCA assay for each sample,
and approximately 50 μg of the resulting homogenate
was separated on 10.5-14% Tris-glycine or 10-20% Tris-
tricine gels for quantitation of APP levels (BioRad
Criterion). After transfer to nitrocellulose (Schleicher
and Schuell Optitran), blots were probed with mouse
anti-human APP/Aβ antibody 6E10 (1:2000 or 1:5000,
Signet #9300-02), or with rabbit anti-APP C-terminal
fragment antibody CT15 (1:2000, kind gift of Eddie
Koo), either in conjunction with or followed by
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body (1:5000, Millipore Ab2302). Binding was detected
with HRP-labeled secondary antibodies and developed
with ECL reagent (Millipore Immobilon). Chemilumin-
escence was measured with a Fuji LAS-4000 mini CCD
system and quantified using Multi Gauge software.
Histology
Immersion-fixed hemibrains were cryoprotected and
embedded 40 per block in a solid matrix. Coronal sec-
tions were cut from the frozen block at 35μm (Multi-
BrainTM processing by NeuroScience Associates,
Knoxville, TN) and stored in cryoprotectant at −20°C
until use. Amyloid was detected from a 1 in 12
series of sections using the Campbell-Switzer silver
stain. A detailed protocol for this stain can be found




Sections were analyzed using a macro written for Axio-
Vision 4.7. Color thresholds were used to identify amyl-
oid plaques in high-resolution digital scans of the
stained slides. Background staining and shading artifacts
were manually excluded from the analyses. The region
of interest was specified by tracing the cortex of the cor-
responding section and the area of pixels above thresh-
old computed relative to the total area for the region of
interest. Four sections spaced at 420 μm intervals span-
ning approximately −1.3 to −2.7 mm from bregma [60]
were analyzed for each animal.
Statistics
All statistics were done using Prism 5.0. Comparisons of
multiple groups were done by one-way ANOVA or two-
way ANOVA followed by Tukey or Bonferroni post hoc
test, respectively. Comparisons limited to two groups
were done by Student’s t-test with Welch’s correction for
unequal variances where appropriate. All graphs display
group mean ± SEM.
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